SCHEMBL215710

SCHEMBL215710

N#CNC(=N)Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
ATM Q13315 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HSD17B10 Q99714 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
CYP2D6 P10635 1/20 0.33
P2RX7 Q99572 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 2/20 0.32
ALOX15 P16050 1/20 0.32
LTA4H P09960 1/20 0.32
TSHR P16473 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10753462 0.79 LMNA (0.49) KMT2AHSD17B10CYP1A2CYP2C9CYP2C19
SCHEMBL3086433 0.76 LTA4H (0.39) KMT2AATMTDP1L3MBTL1HSD17B10
SCHEMBL2767214 0.76 KMT2A (0.47) KMT2AATMTDP1L3MBTL1HSD17B10
SCHEMBL12285498 0.74 RAD51 (0.39) ATMTDP1L3MBTL1HSD17B10RAB9A
SCHEMBL22460487 0.73 KMT2A (0.39) KMT2ACYP1A2CYP2C9CYP2C19GAA
SCHEMBL27682370 0.72 TDP1 (0.36) KMT2AATMTDP1L3MBTL1HSD17B10
SCHEMBL10994431 0.72 TACR1 (0.32) KMT2ACYP1A2CYP2C9CYP2C19GAA
SCHEMBL10656070 0.72 KMT2A (0.59) KMT2AATMTDP1CYP1A2CYP2C9
SCHEMBL10656076 0.72 KMT2A (0.59) KMT2AATMTDP1CYP1A2CYP2C9
SCHEMBL4789929 0.71 ALDH1A1 (0.46) KMT2ATDP1HSD17B10CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109097-A2 NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-05-30 WO disclosed
US-20250171419-A1 NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-05-29 US disclosed
US-8088766-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA INC. (US) 2012-01-03 US disclosed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 US disclosed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 EP disclosed
US-7524852-B2 Bicyclic pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-04-28 US disclosed
US-7488823-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA, INC. (US) 2009-02-10 US disclosed
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-01-08 US disclosed
EP-1532103-A4 USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS BRISTOL MYERS SQUIBB CO (US) 2008-03-05 EP disclosed
US-20020143176-A1 Compounds derived from an amine nucleus and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY 2002-10-03 US disclosed
US-6399773-B1 AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS BRISTOL-MYERS SQUIBB CO. 2002-06-04 US disclosed
EP-1126843-A1 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-29 EP disclosed
WO-2000025780-A1 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 WO disclosed
US-4957920-A INOTROPIC HEUMANN PHARMA GMBH & CO. (DE) 1990-09-18 US disclosed
US-4661520-A Cyanoguanidine useful as an animal growth promoting agent THE DOW CHEMICAL COMPANY (US) 1987-04-28 US disclosed
EP-0190037-A1 Process for preparing an aziridine derivative SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1986-08-06 EP disclosed
US-4514400-A Cardiotonic 5-heteroaryl-pyridone WILLIAM H. RORER, INC. (US) 1985-04-30 US disclosed
EP-0051067-A1 TRIAZINE SYNTHESIS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1982-05-12 EP disclosed
WO-1981003020-A1 TRIAZINE SYNTHESIS COMMW SCIENT IND RES ORG (AU) 1981-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ERBB2, GRB2, EGFR KMT2A 2763/4885ATM 933/4885TDP1 3048/4885
US-20100004298-A1 P-38 INHIBITORS MAPK8, MAPK1, MAP3K8 KMT2A 3683/4885ATM 647/4885TDP1 742/4885
US-20020143176-A1 Compounds derived from an amine nucleus and pharmaceutical compositions comprising same IMPDH1, IMPDH2, IMPA1 KMT2A 2006/4885ATM 1367/4885TDP1 1408/4885
US-20250171419-A1 NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF NAMPT, NAPRT, NNMT KMT2A 374/4885ATM 2980/4885TDP1 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.